Stock TCON TRACON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus TRACON Pharmaceuticals, Inc.

Equities

TCON

US89237H3084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
1.96 USD -7.11% Intraday chart for TRACON Pharmaceuticals, Inc. -16.95% -44.03%
Apr. 03 TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned CI
Mar. 06 HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating MT

Evolution of the average Target Price on TRACON Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

16c63e077d7.6h44lzWHBgAbaI3dciesHgj2_BLgKB42pKxGHJ8AdnQ.2C5Up1DMNjRXEr6IHk3JcEOitEiqZi9jye8VSvVlLgyBUmjlQ8xEVn0ytQ~ba5dee7487f2242bd607fcd3860aec83

Analyst Recommendations on TRACON Pharmaceuticals, Inc.

HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating MT
JonesTrading Downgrades TRACON Pharmaceuticals to Hold From Buy MT
Baird Trims Price Target on TRACON Pharmaceuticals to $3 From $7, Maintains Outperform Rating MT
TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial CI
Maxim Adjusts TRACON Pharmaceuticals' Price Target to $3 From $8, Keeps Buy Rating MT
Baird Trims Price Target on TRACON Pharmaceuticals to $7 From $8, Maintains Outperform Rating MT
TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial CI
Wall Street Set for Gains Ahead of Fed's Rate Decision MT
Baird Starts TRACON Pharmaceuticals at Outperform With $10 Price Target MT
Maxim Group Adjusts TRACON Pharmaceuticals Price Target to $8 From $10, Maintains Buy Rating MT
TRACON PHARMACEUTICALS : Alliance Global Initiates Coverage on TRACON Pharmaceuticals With Buy Rating, $13 Price Target MT
TRACON PHARMACEUTICALS : BTIG Upgrades TRACON Pharmaceuticals to Buy From Neutral; Price Target is $14 MT
TRACON PHARMACEUTICALS : JonesTrading Starts TRACON Pharmaceuticals at Buy With $17 Price Target MT
TRACON PHARMACEUTICALS : HC Wainwright Adjusts TRACON Pharmaceuticals' Price Target to $12 From $7, Keeps at Buy MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.11 USD
Average target price
37.5 USD
Spread / Average Target
+1,677.25%
High Price Target
55 USD
Spread / Highest target
+2,506.64%
Low Price Target
20 USD
Spread / Lowest Target
+847.87%

Consensus detail

Consensus revision (last 18 months)

Analysts covering TRACON Pharmaceuticals, Inc.

HC Wainwright
JonesTrading Institutional Services
Baird
Maxim
Alliance Global Partners
BTIG

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. TCON Stock
  4. Consensus TRACON Pharmaceuticals, Inc.